Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of Ustekinumab in Adult Japanese Subjects With Severe Atopic Dermatitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Apr 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ustekinumab (Primary)
  • Indications Atopic dermatitis
  • Focus Therapeutic Use
  • Sponsors Janssen Pharmaceutical KK

    • Most Recent Events

    • 24 Mar 2017 Primary endpoint (Percent change from Baseline to Week 12 in the Eczema Area and Severity Index (EASI) score) has not been met,according to the results published in the British Journal of Dermatology.
    • 24 Mar 2017 Results published in the British Journal of Dermatology
    • 15 Feb 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top